![Abdul Mullick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Abdul Mullick
Amministratore Delegato presso
KYOWA KIRIN CO., LTD.
Profilo
Abdul Mullick is President, CEO, COO & Representative Director at Kyowa Kirin Co., Ltd. since 2026 and Director at Orchard Therapeutics Plc since 2024.
Former roles include President & Chief Executive Officer at Kyowa Kirin International Plc from 2018 to 2023, Director at Mereo BioPharma Group Plc in 2022, Head-Global Strategic Marketing at Vifor Pharma Management AG from 2014 to 2018, Senior Director-European Business Unit at Endocrine Pharmaceuticals Ltd., Senior Director-Global Brand & Diabetes at Novartis Pharma AG, Vice President, GM-Endocrinology & Cardiology at Genzyme Corp.
Education includes a doctorate from the University of Bristol.
Posizioni attive di Abdul Mullick
| Società | Posizione | Inizio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Direttore/Membro del Consiglio | 24/01/2024 |
| KYOWA KIRIN CO., LTD. | Amministratore Delegato | 01/03/2026 |
Precedenti posizioni note di Abdul Mullick
| Società | Posizione | Fine |
|---|---|---|
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes antibodies, cell & gene therapies for hematological, bone, mineral, haemato-oncology and rare diseases | Amministratore Delegato | 01/01/2023 |
| MEREO BIOPHARMA GROUP PLC | Direttore/Membro del Consiglio | 10/11/2022 |
Vifor Pharma Management AG
 Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals products for the treatment of iron deficiency | Corporate Officer/Principal | 01/04/2018 |
Endocrine Pharmaceuticals Ltd.
 Endocrine Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Develops hormonal drugs | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Formazione di Abdul Mullick
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
15
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes antibodies, cell & gene therapies for hematological, bone, mineral, haemato-oncology and rare diseases | Health Technology |
University of Bristol
 University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Endocrine Pharmaceuticals Ltd.
Endocrine Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Develops hormonal drugs | Commercial Services |
Kyowa Kirin Co., Ltd.
 Kyowa Kirin Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals; develops biochemical reagents and other chemicals | Health Technology |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals products for the treatment of iron deficiency | Health Technology |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
